Phelan-McDermid Syndrome, page-78

In the event that Acadia makes a "friendly / agreeable" move on NEU early 2024, and given that Jon & the Board cut a hard deal, then I think it could play out something like the following:
* NEU would appoint a professional biotech valuer to come up with a DCF value for Trof / Daybue in North America for Rett
* Similarly for Trof / Daybue in ROW taking Acadia
* Similarly for Trof / Daybue for F-X in North America and ROW
* Assuming current Ph 2 trial for PMD using 2591 delivers the good, then NEU would already know by end December 2024 if the other 3 x Ph 2 2591 trials look like also being successful by mid 2024. Remember 5 x market potential of Trof WW. Appoint a professional valuer to come up with a value.
* Now for up front milestone payments. I think NEU / Jon would push Acadia to pay out all Trof / Daybue milestone payments for North America up front.
* NEU cash balance of money in the bank plus up-front Nth America milestone payments (less taxes and expenses) would be distributed to NEU shareholders as a special dividend payment
* Then Acadia would make a share only take-over offer for the shares in NEU at a premium (for lost opportunity) of the sum of the valuations that NEU presents to them.

Jon & NEU Board to drive a very hard bargain after the many years of hard work it has taken to get to this point.

IMHO

GLTA